Back

Low rates of haemorrhagic stroke, not increased by age, renal/hepatic impairment, concomitant anti-platelet use and high CHA2DS2-VASc scores, in the 4-year follow-up of ETNA-AF-Europe

2 September 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: New findings in stroke Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Raffaele De Caterina

University of Pisa, Pisa (Italy)

8 More presentations in this session

Presentation thumbnail
Cardiac autonomic changes after stroke
Doctor M. Schreinlechner (Innsbruck, AT)
Abstract Slides Video
Presentation thumbnail
Apolipoprotein C3-rich low-density lipoprotein (AC3RL) exacerbates cerebral ischaemic stroke injury by increasing BBB leakage via LOX-1
Miss P. Tsai (Taichung, TW)
Abstract Slides Video
Presentation thumbnail
Machine learning identification of risk factors for ischaemic stroke in patients with heart failure with reduced ejection fraction but without atrial fibrillation: A report from WARCEF trial
Doctor B. Huang (Chongqing, CN)
Abstract Slides Video
Presentation thumbnail
Imaging signs of carotid plaque vulnerability predict subclinical neurological events in asymptomatic patients: the carotid artery multi-modality imaging prognostic study
Doctor L. Gargani (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Oral anticoagulants or antiplatelets for cryptogenic stroke: a systematic review and meta-analysis
Doctor P. Lee (Bronx, US)
Abstract Slides Video

Access the full session

Session thumbnail
New findings in stroke

The Event

Event poster

ESC Congress 2024

2 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study
thumbnail
Congress Presentation
AF patients in routine practice: a long-term perspective from ETNA-AF-Europe
thumbnail
Congress Presentation
Decreased risk of cardiovascular events in patients with atrial fibrillation treated with lipid-lowering therapy: 2-year follow-up of the Global ETNA-AF program

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources